NCT05390151

Brief Summary

Randomised Controlled Trial comparing Laser assisted closure of transsphincteric fistula to the rectal advancement flap.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
176

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 25, 2022

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

June 15, 2022

Status Verified

March 1, 2022

Enrollment Period

3.5 years

First QC Date

April 21, 2022

Last Update Submit

June 14, 2022

Conditions

Keywords

Rectal, Advancement FlapLaser assisted Fistula ClosureRandomised Control Trial

Outcome Measures

Primary Outcomes (1)

  • Primary fistula closure after index laser or flap treatment

    Success rate (number of patients) of laser/flap treatment defined as full healing (fistula closure) after the index procedure

    6 months

Secondary Outcomes (8)

  • Secondary Fistula closure

    6 months

  • Postoperative Pain

    6 months

  • Postoperative fecal incontinence

    6 months

  • Postoperative wound complications

    6 months

  • Postoperative Quality of Life

    6 months

  • +3 more secondary outcomes

Study Arms (2)

Laser assisted fistula closure

ACTIVE COMPARATOR

Group to be actively treated with laser assisted fistula surgery

Procedure: Laser treatment of anal fistula

Rectal advancement flap

ACTIVE COMPARATOR

Group to be actively treated with a rectal advancement flap.

Procedure: RAF

Interventions

using a radial laserprobe to treat transsphincteric fistula

Also known as: FiLAC - LAFT
Laser assisted fistula closure
RAFPROCEDURE

current golden standard in transsphincteric fistula surgery

Also known as: rectal advancement flap
Rectal advancement flap

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with fistula involving more than one-third of the external anal sphincter
  • Age ≥ 18
  • Able to complete an informed written consent, understand its implications and contents, and participate in follow-up

You may not qualify if:

  • Fistula tract \< 1 cm
  • Complex fistula tract system (branching of fistula tract inside the sphincter complex)
  • Pregnancy
  • HIV-positive
  • Crohn´s disease, Ulcerative colitis
  • Fistula due to malignancy
  • Tuberculosis
  • Hidradenitis Suppurativa
  • No internal opening
  • Unable to undergo or contraindications to MRI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Antwerp University Hospital

Edegem, Antwerpen, 2610, Belgium

RECRUITING

Az St Dimpna Geel

Geel, Antwerpen, 2440, Belgium

RECRUITING

Jessa Ziekenhuis Hasselt

Hasselt, Limburg, 3500, Belgium

RECRUITING

Gent University Hospital

Ghent, Oost- Vlaanderen, 9000, Belgium

NOT YET RECRUITING

Brussels University Hospital

Brussels, 1090, Belgium

NOT YET RECRUITING

MeSH Terms

Conditions

Rectal Fistula

Condition Hierarchy (Ancestors)

Intestinal FistulaDigestive System FistulaDigestive System DiseasesIntestinal DiseasesGastrointestinal DiseasesRectal DiseasesFistulaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Niels Komen, M.D. Phd

    University Hospital, Antwerp

    STUDY CHAIR
  • Sander Van Hoof, M.D.

    University Hospital, Antwerp

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sander Van Hoof, M.D.

CONTACT

Niels Komen, M.D. Phd

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2022

First Posted

May 25, 2022

Study Start

March 1, 2022

Primary Completion

September 1, 2025

Study Completion

March 1, 2026

Last Updated

June 15, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations